Detalhe da pesquisa
1.
Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil.
J Inherit Metab Dis
; 45(2): 340-352, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34910312
2.
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
Pediatr Blood Cancer
; 62(8): 1427-36, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-25810327
3.
Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.
Hum Vaccin
; 7(10): 1060-5, 2011 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-21941091
4.
Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of age.
Hum Vaccin
; 7(5): 549-56, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21441781
5.
Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study.
BMC Infect Dis
; 10: 134, 2010 May 26.
Artigo
Inglês
| MEDLINE | ID: mdl-20504306
6.
Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag).
Open Forum Infect Dis
; 7(1): ofz532, 2020 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-31993453
7.
Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.
BMC Med
; 7: 16, 2009 Apr 14.
Artigo
Inglês
| MEDLINE | ID: mdl-19366435
8.
Safety of a refrigerator-stable varicella vaccine (VARIVAX) in healthy 12- to 15-month-old children: A randomized, double-blind, cross-over study.
Hum Vaccin
; 5(7): 455-60, 2009 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-19305145
9.
Immunogenicity and safety of PNEUMOVAX II manufactured by a new process in older adults.
Hum Vaccin
; 5(9): 608-13, 2009 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-19617717
10.
Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial.
Hum Vaccin
; 5(5): 315-21, 2009 May.
Artigo
Inglês
| MEDLINE | ID: mdl-19011374
11.
Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age.
Hum Vaccin Immunother
; 15(4): 778-785, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-30481110
12.
Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Vaccine
; 34(30): 3454-62, 2016 06 24.
Artigo
Inglês
| MEDLINE | ID: mdl-27155493
13.
Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
Hum Vaccin Immunother
; 9(4): 858-64, 2013 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-23319176
14.
Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
Vaccine
; 30(20): 3082-9, 2012 Apr 26.
Artigo
Inglês
| MEDLINE | ID: mdl-22406278
15.
Challenge with a hepatitis B vaccine in two cohorts of 4-7-year-old children primed with hexavalent vaccines: an open-label, randomised trial in Italy.
Vaccine
; 30(39): 5770-5, 2012 Aug 24.
Artigo
Inglês
| MEDLINE | ID: mdl-22789511
16.
Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin.
Pediatr Infect Dis J
; 31(11): 1166-72, 2012 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-22772170
17.
Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine.
Clin Vaccine Immunol
; 18(5): 878-84, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21389149
18.
Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine.
Vaccine
; 27(37): 5096-102, 2009 Aug 13.
Artigo
Inglês
| MEDLINE | ID: mdl-19573637
19.
Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants.
Hum Vaccin
; 2(5): 215-21, 2006.
Artigo
Inglês
| MEDLINE | ID: mdl-17035735